Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255460 | 0.96 | FDFT1 (0.79) | FDFT1 | |
| SCHEMBL4110605 | 0.94 | FDFT1 (0.77) | FDFT1 | |
| SCHEMBL7250667 | 0.94 | FDFT1 (0.77) | FDFT1 | |
| SCHEMBL7249844 | 0.93 | FDFT1 (0.78) | FDFT1 | |
| SCHEMBL7253082 | 0.93 | FDFT1 (0.78) | FDFT1 | |
| SCHEMBL7255846 | 0.93 | FDFT1 (0.68) | FDFT1 | |
| SCHEMBL7250265 | 0.93 | FDFT1 (0.83) | FDFT1 | |
| SCHEMBL4105268 | 0.92 | FDFT1 (0.76) | FDFT1 | |
| SCHEMBL7253147 | 0.92 | FDFT1 (0.76) | FDFT1 | |
| SCHEMBL6989471 | 0.92 | FDFT1 (0.75) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | claimed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | claimed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | claimed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | claimed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | disclosed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.